深潮TechFlow
深潮TechFlow|11月 16, 2026 01:05
[Hong Kong Stock Market News: Goldman Sachs Upgrades China H-Shares Rating, BYD Responds to Acquisition Rumors] According to TechFlow, on November 16th, Goldman Sachs upgraded its rating on China H-shares to "Overweight." Regarding rumors of a digital energy company being sold to BYD, BYD stated that there is no factual basis for such a claim. Regarding Hong Kong-listed companies, radiopharmaceutical company Siasun Pharmaceuticals will begin its IPO today until November 19th, with an offer price of HK$52 to HK$68 per share, offering 6.561 million H-shares. Jingfang Pharmaceuticals stated that its GFH276 pancreatic cancer combination therapy study has completed the first patient dosing in China and overseas. Furthermore, Simcere Pharmaceutical's Siasun sublingual tablets and Innovent Biologics' zolectretinib have been included in the new version of the National Reimbursement Drug List; Fosun Pharma stated that several products of the company and its subsidiaries have been included for the first time, have had their notes adjusted, or have been transferred to regular drug list management.
+4
Mentioned
Share To

Timeline

HotFlash

APP

X

Telegram

Facebook

Reddit

CopyLink

Hot Reads